Frailty in men and women with fatty liver disease linked to metabolic problems
Compares frailty between men and women who have MASLD.
Key facts
- Who runs it
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Where
- Barcelona, SpainSee the site
- Trial code
- Registry title
- Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.
- Status
- Recruiting
- People taking part
- 140 people, planned
- Started
- 26 May 2026
- Expected to end
- 25 May 2028
- Type of study
- Observational
- Record updated
- 17 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 20 to 80 with fatty liver disease linked to metabolic problems (MASLD). It studies frailty, thinking and quality of life in men and women.
- Age
- 20 to 80 years
- Sex
- Men and women
- Disease stage
- Fatty liver disease linked to metabolic dysfunction (MASLD). No stage is given.
Main reasons for not taking part
- Risky alcohol use: more than 30 g/day in men or more than 20 g/day in women
- Other liver diseases, such as viral hepatitis or autoimmune hepatitis
- Advanced neurodegenerative diseases or severe psychiatric disorders
- Severe other illnesses or treatments that may affect frailty and quality of life more than the liver disease
- Not able to give informed consent or take part in regular check-ups
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients will be included who are able to provide informed consent and actively participate in periodic assessments
Who cannot take part
- Other liver diseases (viral hepatitis, autoimmune hepatitis, etc.)
- Advanced neurodegenerative diseases or severe psychiatric disorders
- Severe comorbidities or treatments that, in the researchers' judgment, may affect frailty and quality of life more than metabolic syndrome and liver disease
- Risky alcohol consumption:; > 30 g/day in men and > 20 g/day in women. AUDIT score: > 7 points in men, > 5 in women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 80 years old?
Where in Spain
- Hospital de la Santa Creu i Sant PauBarcelona, SpainContact: Eva Román, Digestive Pathology NurseNot yet recruiting
About the trial
What the trial wants to find out
The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.
The group in the trial
- Patients diagnosed with MASLD
Consecutive patients diagnosed with MASLD at any degree of fibrosis between the ages of 20 and 80 will be included. The main variable will be the degree of frailty assessed by the LFI and the Fried Index.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- IIBSP-MAS-2025-133
- Plain-language title
- Frailty in men and women with fatty liver disease linked to metabolic problemsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07652892, who can take part
- Record updated
- 17 June 2026